Kubota Pharma Sees Revenue Boost From

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 17, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Kubota Pharma Sees Revenue Boost From China Expansion; Targets Early Commercialization in Europe

Source disclosure: February 17, 2026 Kubota Pharmaceutical Holdings Co.,Ltd. [4596.T] TOKYO, Feb 17 (Pulse News Wire) – Kubota Pharmaceutical Holdings CO.,LTD. (4596.T) reported a reduction in operating expenses compared to its initial budget for fiscal 2025. Cash reserves increased by ¥2.025 billion from the previous balance, reaching ¥15.944 billion by December 2025. The company also noted significant progress in expanding its wearable nearsightedness device, Kubota Glass®, into t